Pharma Industry Pushes A Broadened Meaning For “Orphan”
Executive Summary
BOSTON – Along with the surge in interest in drugs to treat rare or orphan diseases, there has been an increasingly strategic view of what qualifies as an orphan market, with companies looking to subdivide conditions to capitalize on the perceived advantages afforded by rare diseases, according to participants at the recent BioPharm America conference.
You may also be interested in...
Will March 2012 Mark The End Of Regulatory Limbo For Discovery’s Surfaxin?
Discovery Laboratories now believes March 2012 could mark the end of an almost eight-year regulatory odyssey to secure FDA approval of its synthetic surfactant Surfaxin (lucinactant).
Will March 2012 Mark The End Of Regulatory Limbo For Discovery’s Surfaxin?
Discovery Laboratories now believes March 2012 could mark the end of an almost eight-year regulatory odyssey to secure FDA approval of its synthetic surfactant Surfaxin (lucinactant).
Will March 2012 Mark The End Of Regulatory Limbo For Discovery's Surfaxin?
FDA has set a March 6 user fee date for action on Discovery Laboratories' synthetic surfactant, which was filed with the agency in 2004 but is now in its fifth review cycle.